Exelixis Inc (EXEL) concluded trading on Wednesday at a closing price of $37.27, with 2.65 million shares of worth about $98.88 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 63.75% during that period and on January 15, 2025 the price saw a gain of about 4.54%. Currently the company’s common shares owned by public are about 285.78M shares, out of which, 278.50M shares are available for trading.
Stock saw a price change of 8.94% in past 5 days and over the past one month there was a price change of 5.94%. Year-to-date (YTD), EXEL shares are showing a performance of 11.92% which increased to 64.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $20.01 but also hit the highest price of $36.97 during that period. The average intraday trading volume for Exelixis Inc shares is 2.35 million. The stock is currently trading 8.41% above its 20-day simple moving average (SMA20), while that difference is up 6.56% for SMA50 and it goes to 38.59% higher than SMA200.
Exelixis Inc (NASDAQ: EXEL) currently have 285.78M outstanding shares and institutions hold larger chunk of about 87.71% of that.
The stock has a current market capitalization of $10.64B and its 3Y-monthly beta is at 0.53. PE ratio of stock for trailing 12 months is 23.75, while it has posted earnings per share of $1.57 in the same period. Its PEG reads 0.65 and has Quick Ratio of 3.88 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EXEL, volatility over the week remained 3.92% while standing at 2.75% over the month.
Stock’s fiscal year EPS is expected to rise by 164.54% while it is estimated to increase by 10.28% in next year. EPS is likely to grow at an annualized rate of 36.32% for next 5-years, compared to annual growth of -21.77% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on December 20, 2024 offering a Market perform rating for the stock and assigned a target price range of between $36 and $40 to it. Coverage by BofA Securities stated Exelixis Inc (EXEL) stock as a Neutral in their note to investors on December 17, 2024, suggesting a price target of $39 for the stock. On October 16, 2024, RBC Capital Mkts Reiterated their recommendations, while on September 19, 2024, UBS Initiated their ratings for the stock with a price target of $30. Stock get an Equal weight rating from Barclays on April 11, 2024.
